<?xml version="1.0" encoding="UTF-8"?>
<gtr:projectOverview xmlns:gtr="http://gtr.ukri.org/api"><gtr:projectComposition><gtr:collaborations/><gtr:leadResearchOrganisation url="http://gtr.ukri.org:80/organisation/83D87776-5958-42AE-889D-B8AECF16B468"><gtr:id>83D87776-5958-42AE-889D-B8AECF16B468</gtr:id><gtr:name>University of Leeds</gtr:name><gtr:department>Inst of Molecular &amp; Cellular Biology</gtr:department><gtr:address><gtr:line1>University of Leeds</gtr:line1><gtr:line4>Leeds</gtr:line4><gtr:line5>West Yorkshire</gtr:line5><gtr:postCode>LS2 9JT</gtr:postCode><gtr:region>Yorkshire and The Humber</gtr:region><gtr:country>United Kingdom</gtr:country></gtr:address><gtr:typeInd>RO</gtr:typeInd></gtr:leadResearchOrganisation><gtr:organisationRoles><gtr:organisationRole url="http://gtr.ukri.org:80/organisation/83D87776-5958-42AE-889D-B8AECF16B468"><gtr:id>83D87776-5958-42AE-889D-B8AECF16B468</gtr:id><gtr:name>University of Leeds</gtr:name><gtr:address><gtr:line1>University of Leeds</gtr:line1><gtr:line4>Leeds</gtr:line4><gtr:line5>West Yorkshire</gtr:line5><gtr:postCode>LS2 9JT</gtr:postCode><gtr:region>Yorkshire and The Humber</gtr:region><gtr:country>United Kingdom</gtr:country></gtr:address><gtr:roles><gtr:role><gtr:name>LEAD_RO</gtr:name></gtr:role></gtr:roles></gtr:organisationRole></gtr:organisationRoles><gtr:personRoles><gtr:personRole url="http://gtr.ukri.org:80/person/D6BC9855-0646-4683-A2E6-565E7CC887DD"><gtr:id>D6BC9855-0646-4683-A2E6-565E7CC887DD</gtr:id><gtr:firstName>Mark</gtr:firstName><gtr:surname>Kearney</gtr:surname><gtr:roles><gtr:role><gtr:name>CO_INVESTIGATOR</gtr:name></gtr:role></gtr:roles></gtr:personRole><gtr:personRole url="http://gtr.ukri.org:80/person/7859D775-EE82-460C-A484-371374FC0E42"><gtr:id>7859D775-EE82-460C-A484-371374FC0E42</gtr:id><gtr:firstName>Martin</gtr:firstName><gtr:surname>Stacey</gtr:surname><gtr:roles><gtr:role><gtr:name>CO_INVESTIGATOR</gtr:name></gtr:role></gtr:roles></gtr:personRole><gtr:personRole url="http://gtr.ukri.org:80/person/9ADE7FDC-0FDC-4756-BE9F-F29E0A697232"><gtr:id>9ADE7FDC-0FDC-4756-BE9F-F29E0A697232</gtr:id><gtr:firstName>Asipu</gtr:firstName><gtr:surname>Sivaprasadarao</gtr:surname><gtr:roles><gtr:role><gtr:name>CO_INVESTIGATOR</gtr:name></gtr:role></gtr:roles></gtr:personRole><gtr:personRole url="http://gtr.ukri.org:80/person/61BD88A8-A12A-4410-A191-EABDB2F06EB5"><gtr:id>61BD88A8-A12A-4410-A191-EABDB2F06EB5</gtr:id><gtr:firstName>David</gtr:firstName><gtr:otherNames>John</gtr:otherNames><gtr:surname>Beech</gtr:surname><gtr:roles><gtr:role><gtr:name>PRINCIPAL_INVESTIGATOR</gtr:name></gtr:role></gtr:roles></gtr:personRole><gtr:personRole url="http://gtr.ukri.org:80/person/797B9B58-4235-4B8B-ABC5-9B954B283A0C"><gtr:id>797B9B58-4235-4B8B-ABC5-9B954B283A0C</gtr:id><gtr:firstName>Karen</gtr:firstName><gtr:otherNames>Elizabeth</gtr:otherNames><gtr:surname>Porter</gtr:surname><gtr:roles><gtr:role><gtr:name>CO_INVESTIGATOR</gtr:name></gtr:role></gtr:roles></gtr:personRole></gtr:personRoles><gtr:project url="http://gtr.ukri.org:80/projects?ref=G0901761"><gtr:id>CA292CBB-3F83-4405-90AF-ECD34A33D83E</gtr:id><gtr:title>Oxidized phospholipid ionic transduction mechanism of human vascular cells</gtr:title><gtr:status>Closed</gtr:status><gtr:grantCategory>Research Grant</gtr:grantCategory><gtr:grantReference>G0901761</gtr:grantReference><gtr:abstractText>At least half of the European population dies from cardiovascular disease, often prematurely and following prolonged periods of disability. There is compelling evidence that this type of disease and several related diseases are caused, or accelerated, by unwanted inflammation, excessive oxidative stress, inactivity, and high fat load. Seminal studies over the past decade have identified special types of fat (lipid) in the disease conditions that are collectively referred to as oxidized phospholipids. There is excellent evidence that oxidized phospholipids play pivotal roles in cardiovascular disease but there is little fundamental understanding of how cells sense or respond to the lipids; or defend against them. In our new studies of vascular cells from patients with cardiovascular disease we have identified a striking initial reception mechanism for the lipids and so propose investigation of how the mechanism works as well as identification of genes that encode the mechanism. Through this work we will provide new insight into an important and poorly understood area of human biology and lay the foundations for valuable therapeutic interventions with high relevance to major human diseases.</gtr:abstractText><gtr:technicalSummary>New data generated by our group have revealed a previously unrecognized monovalent cation-selective membrane current that depends on Orai1 and is triggered by oxidized phospholipids without store-depletion. A similar ionic current can be triggered by store-depletion but we suggest the oxidized phospholipids are the physiological or pathological factors that activate the mechanism. The mechanism may have widespread importance for survival of human cells and be a key element in oxidized phospholipid signaling in inflammation and related cardiovascular diseases. We propose a project that will define molecular components of the mechanism and reveal distinguishing features and tools that will enable investigation of the mechanism in vivo. Using combinations of electrophysiology, calcium measurement and molecular techniques the study will: Characterise the monovalent cationic current and its activation mechanism; Identify molecular tools that specifically manipulate the monovalent cationic current; Investigate RNA editing of Orai1-3 and STIM1-2 because preliminary data suggest that RNA-editing is necessary for the monovalent mechanism but not Orai1-dependent Ca2+-entry; and Identify monovalent cation channel subunits coupled to Orai1. The study will provide important fundamental information about Orai1 and oxidized phospholipid signaling in human cells and may reveal new targets for therapeutic intervention.</gtr:technicalSummary><gtr:fund><gtr:end>2013-11-30</gtr:end><gtr:funder url="http://gtr.ukri.org:80/organisation/C008C651-F5B0-4859-A334-5F574AB6B57C"><gtr:id>C008C651-F5B0-4859-A334-5F574AB6B57C</gtr:id><gtr:name>MRC</gtr:name></gtr:funder><gtr:start>2010-09-01</gtr:start><gtr:type>INCOME_ACTUAL</gtr:type><gtr:valuePounds>576725</gtr:valuePounds></gtr:fund><gtr:output><gtr:artisticAndCreativeProductOutputs/><gtr:collaborationOutputs/><gtr:disseminationOutputs/><gtr:exploitationOutputs/><gtr:furtherFundingOutputs/><gtr:impactSummaryOutputs/><gtr:intellectualPropertyOutputs/><gtr:otherResearchOutputs/><gtr:policyInfluenceOutputs/><gtr:productOutputs/><gtr:researchDatabaseAndModelOutputs/><gtr:researchMaterialOutputs/><gtr:softwareAndTechnicalProductOutputs/><gtr:spinOutOutputs/></gtr:output><gtr:publications><gtr:publication><gtr:id>59401C30-DAD2-4AFD-ACE2-98BF591620F3</gtr:id><gtr:title>Nanomolar potency and selectivity of a Ca&amp;sup2;? release-activated Ca&amp;sup2;? channel inhibitor against store-operated Ca&amp;sup2;? entry and migration of vascular smooth muscle cells.</gtr:title><gtr:parentPublicationTitle>British journal of pharmacology</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/ad7968d586527c1fd3f76aeabf35ac38"><gtr:id>ad7968d586527c1fd3f76aeabf35ac38</gtr:id><gtr:otherNames>Li J</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2011-01-01</gtr:date><gtr:issn>0007-1188</gtr:issn><gtr:outcomeId>pm_13719_29_21545575</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>43DCA851-2392-47E2-A615-7FC3C76AD12E</gtr:id><gtr:title>Inhibition of endothelial cell Ca&amp;sup2;? entry and transient receptor potential channels by Sigma-1 receptor ligands.</gtr:title><gtr:parentPublicationTitle>British journal of pharmacology</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/03ee87158703bb2bf4a0691e5267d00f"><gtr:id>03ee87158703bb2bf4a0691e5267d00f</gtr:id><gtr:otherNames>Amer MS</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2013-01-01</gtr:date><gtr:issn>0007-1188</gtr:issn><gtr:outcomeId>pm_13719_29_23121507</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>97C17647-C778-4E8C-906C-261A7AD75D62</gtr:id><gtr:title>Platelet-derived growth factor maintains stored calcium through a nonclustering Orai1 mechanism but evokes clustering if the endoplasmic reticulum is stressed by store depletion.</gtr:title><gtr:parentPublicationTitle>Circulation research</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/ef09c74e64878f877ca1a9c705e0d2d1"><gtr:id>ef09c74e64878f877ca1a9c705e0d2d1</gtr:id><gtr:otherNames>McKeown L</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2012-01-01</gtr:date><gtr:issn>0009-7330</gtr:issn><gtr:outcomeId>pm_13719_29_22556336</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>4B77101E-EFB4-4F3B-AA82-C071790E9473</gtr:id><gtr:title>Orai1 and CRAC channel dependence of VEGF-activated Ca2+ entry and endothelial tube formation.</gtr:title><gtr:parentPublicationTitle>Circulation research</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/ad7968d586527c1fd3f76aeabf35ac38"><gtr:id>ad7968d586527c1fd3f76aeabf35ac38</gtr:id><gtr:otherNames>Li J</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2011-01-01</gtr:date><gtr:issn>0009-7330</gtr:issn><gtr:outcomeId>pm_13719_29_21441136</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>CFCBC65B-F30F-4AD2-9563-CD5375B02C46</gtr:id><gtr:title>Orai1 calcium channels in the vasculature.</gtr:title><gtr:parentPublicationTitle>Pflugers Archiv : European journal of physiology</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/f3c7ccb3e6f7e6382f148ceef44ef4c1"><gtr:id>f3c7ccb3e6f7e6382f148ceef44ef4c1</gtr:id><gtr:otherNames>Beech DJ</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2012-01-01</gtr:date><gtr:issn>0031-6768</gtr:issn><gtr:outcomeId>pm_13719_29_22402985</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>6C04EB11-0FF3-4728-BEF4-0C8E0E6CD06D</gtr:id><gtr:title>Potent suppression of vascular smooth muscle cell migration and human neointimal hyperplasia by KV1.3 channel blockers.</gtr:title><gtr:parentPublicationTitle>Cardiovascular research</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/1bb68c61b731239ae74d8d6ca5b195da"><gtr:id>1bb68c61b731239ae74d8d6ca5b195da</gtr:id><gtr:otherNames>Cheong A</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2011-01-01</gtr:date><gtr:issn>0008-6363</gtr:issn><gtr:outcomeId>pm_13719_29_20884640</gtr:outcomeId></gtr:publication></gtr:publications><gtr:identifiers><gtr:identifier type="RCUK">G0901761</gtr:identifier></gtr:identifiers><gtr:healthCategories><gtr:healthCategory><gtr:id>D4FDB752-4E9C-491F-9C63-B7D7F6F95417</gtr:id><gtr:percentage>50</gtr:percentage><gtr:text>Cardiovascular</gtr:text></gtr:healthCategory><gtr:healthCategory><gtr:id>C6D70A71-8796-47BC-AFE0-CC2286E66A06</gtr:id><gtr:percentage>50</gtr:percentage><gtr:text>Inflammatory and Immune System</gtr:text></gtr:healthCategory></gtr:healthCategories><gtr:researchActivities><gtr:researchActivity><gtr:id>CF950C9A-DB16-4E23-8AEB-94548777BCA1</gtr:id><gtr:percentage>50</gtr:percentage><gtr:text>1.1  Normal biological development and functioning</gtr:text></gtr:researchActivity><gtr:researchActivity><gtr:id>1BF330A9-C7B5-49C5-B54B-CF4FAE6DF1D8</gtr:id><gtr:percentage>50</gtr:percentage><gtr:text>2.1  Biological and endogenous factors</gtr:text></gtr:researchActivity></gtr:researchActivities><gtr:researchSubjects/><gtr:researchTopics/><gtr:rcukProgrammes/></gtr:project></gtr:projectComposition></gtr:projectOverview>